Esorubicin hydrochloride (BioDeep_00000840060)

   


代谢物信息卡片


Esorubicin hydrochloride

化学式: C27H30ClNO10 (563.1558150000001)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1CC(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N.Cl
InChI: /m0./s1

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D000970 - Antineoplastic Agents

同义名列表

1 个代谢物同义名

Esorubicin hydrochloride



数据库引用编号

4 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • P Genne, M T Dimanche-Boitrel, R Y Mauvernay, G Gutierrez, O Duchamp, J M Petit, F Martin, B Chauffert. Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo. Cancer research. 1992 May; 52(10):2797-801. doi: . [PMID: 1581892]
  • J A Kish, J F Ensley, M al-Sarraf. Phase II evaluation of 4'deoxydoxorubicin in advanced renal cell carcinoma. American journal of clinical oncology. 1990 Feb; 13(1):17-8. doi: 10.1097/00000421-199002000-00005. [PMID: 2305717]
  • P Genne, B Coudert, H Pelletier, C Girardot, F Martin, B Chauffert. Serum concentrations of amiodarone required for an in vivo modulation of anthracycline resistance. Anticancer research. 1989 Nov; 9(6):1655-9. doi: NULL. [PMID: 2627117]
  • P Hurteloup, P Chollet, H Roche, B Chevallier, P Cappelaere, M Van Glabbece, M Hayat, J P Armand. Phase II trial of esorubicin in advanced renal carcinoma. Clinical Screening Group of the EROTC. European journal of cancer & clinical oncology. 1989 Jun; 25(6):995-6. doi: 10.1016/0277-5379(89)90161-2. [PMID: 2753061]
  • W Kreis, C Rottach, D R Budman, K Chan, P Schulman, S L Allen, L Weiselberg, V Vinciguerra. Pharmacokinetic and phase I evaluation of esorubicin (4'-deoxydoxorubicin) by continuous infusion over forty-eight hours in patients with leukemia. Cancer research. 1988 Oct; 48(19):5580-4. doi: NULL. [PMID: 3166400]
  • J Robert. [Pharmacokinetics of new anthracyclines]. Bulletin du cancer. 1988; 75(2):167-74. doi: . [PMID: 3282579]
  • R W Carlson, R D Williams, M E Billingham, M Kohler, F M Torti. Phase II trial of esorubicin in the treatment of metastatic carcinoma of the kidney: a study of the Northern California Oncology Group. Cancer treatment reports. 1987 Jul; 71(7-8):767-8. doi: NULL. [PMID: 3607787]
  • V Zagonel, U Tirelli, R Sorio, S Frustaci, M A Pacciarini, N Di Pietro. 4'-Deoxydoxorubicin (esorubicin) in non-Hodgkin's lymphomas and plasma cell tumors: first evidence of activity. Haematologica. 1987 Jan; 72(1):97-9. doi: NULL. [PMID: 3108102]
  • J Cummings, D J Kerr, S B Kaye. Occurrence of circulating 7-deoxyaglycone metabolites of 4'-deoxydoxorubicin in man. Cancer chemotherapy and pharmacology. 1987; 20(3):263-4. doi: 10.1007/bf00570499. [PMID: 3677300]
  • E A Griffin, J M Vanderkooi, G Maniara, M Erecińska. Anthracycline binding to synthetic and natural membranes. A study using resonance energy transfer. Biochemistry. 1986 Dec; 25(24):7875-80. doi: 10.1021/bi00372a013. [PMID: 3467794]
  • A T van Oosterom, A V Bono, S B Kaye, T A Splinter, A Calciati, S D Fosså, M de Pauw, R Sylvester. 4'Deoxydoxorubicin in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group. European journal of cancer & clinical oncology. 1986 Dec; 22(12):1531-2. doi: 10.1016/0277-5379(86)90091-x. [PMID: 3595678]
  • J Cummings, J G Morrison, N Willmott. Determination of anthracycline purity in patient samples and identification of in vitro chemical reduction products by application of a multi-diode array high-speed spectrophotometric detector. Journal of chromatography. 1986 Sep; 381(2):373-84. doi: 10.1016/s0378-4347(00)83603-8. [PMID: 3463565]
  • S Wadler, J Z Fuks, P H Wiernik. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. Journal of clinical pharmacology. 1986 Sep; 26(7):491-509. doi: 10.1002/j.1552-4604.1986.tb02942.x. [PMID: 2944917]
  • J Cummings, R Milroy. In vitro formation of a toxic aglycone metabolite of 4-demethoxydaunorubicin in conditions that parallel the stomach. Anticancer research. 1986 Sep; 6(5):1177-9. doi: NULL. [PMID: 3467647]
  • J H Beijnen, J M Van der Nat, R P Labadie, W J Underberg. Decomposition of mitomycin and anthracycline cytostatics in cell culture media. Anticancer research. 1986 Jan; 6(1):39-43. doi: NULL. [PMID: 3082277]
  • T A Braich, S E Salmon, A Robertone, D S Alberts, S E Jones, T P Miller, H S Garewal. Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma. Investigational new drugs. 1986; 4(3):269-74. doi: 10.1007/bf00179595. [PMID: 3818231]
  • J Cummings. Method for the determination of 4'-deoxydoxorubicin, 4'-deoxydoxorubicinol and their 7-deoxyaglycones in human serum by high-performance liquid chromatography. Journal of chromatography. 1985 Jun; 341(2):401-9. doi: 10.1016/s0378-4347(00)84053-0. [PMID: 4030989]
  • G F Stanton, V Raymond, R E Wittes, P Schulman, D Budman, R Baratz, L Williams, G R Petroni, N L Geller, C Hancock. Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer. Cancer research. 1985 Apr; 45(4):1862-8. doi: NULL. [PMID: 3978646]
  • P Dodion, T A Davis, M Rozencweig, N Crespeigne, Y Kenis, N R Bachur. Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin). Investigational new drugs. 1985; 3(4):361-8. doi: 10.1007/bf00170759. [PMID: 4086243]
  • H Weenen, J M van Maanen, M M de Planque, J G McVie, H M Pinedo. Metabolism of 4'-modified analogs of doxorubicin. unique glucuronidation pathway for 4'-epidoxorubicin. European journal of cancer & clinical oncology. 1984 Jul; 20(7):919-26. doi: 10.1016/0277-5379(84)90165-2. [PMID: 6589165]
  • Y M Peng, D S Alberts, S E Salmon, T P Davis. A method for the simultaneous measurement of the new anthracycline derivative 4'-deoxydoxorubicin and its metabolites by reversed phase liquid chromatography. Investigational new drugs. 1984; 2(3):277-80. doi: 10.1007/bf00175377. [PMID: 6511234]